Article Sidebar

PDF
Date Published: 05/07/2023
Abstract Views: 212
Views PDF: 211
DOI: https://doi.org/10.51298/vmj.v527i2.5854
Issue
Vol. 527 No. 2 (2023)
Section
Các bài báo
How to Cite
Ong , T. D., Phùng , L. T., Đỗ, Q. T., Đỗ, T. M., & Nguyễn, T. V. (2023). COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT WITH FIRST-LINE AFATINIB VERSUS OSIMERTINIB IN NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION IN VIETNAM. Vietnam Medical Journal, 527(2). https://doi.org/10.51298/vmj.v527i2.5854

COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT WITH FIRST-LINE AFATINIB VERSUS OSIMERTINIB IN NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION IN VIETNAM

Thế Duệ Ong 1, Lâm Tới Phùng 1,, Quỳnh Trang Đỗ1, Trà My Đỗ1, Tuấn Việt Nguyễn1
1 Institute of Health Strategy & Policy - Ministry of Health

Main Article Content

Abstract

Objective: To evaluate the cost-effectiveness of sequential treatment with first-line Afatinib versus Osimertinib in the treatment of non-small cell lung cancer with EGFR mutation in Vietnam. Methods: The decision tree model was built to estimate the cost-effectiveness of two treatment sequences, applying the payer's perspective. Clinical efficacy parameters are compiled from published clinical trials to estimate progression-free survival and treatment costs of each treatment line. Treatment cost parameters and adverse event management are collected based on clinical expert consultation. Results: The sequential treatment with first-line Afatinib had a greater mean time on treatment than that of Osimertinib, at 29.2 months and 24.8 months, respectively. Compared to the sequential treatment with first-line Osimertinib, the sequential treatment with first-line Afatinib is cost-effective. Conclusion: The sequential treatment with first-line Afatinib is cost-effective when compared to that of Osimertinib in the treatment of non-small cell lung cancer with EGFR mutation in Vietnam

Article Details

Keywords

Non-small cell lung cancer, cost-effectiveness, afatinib, osimertinib

References

1. Soria, J.C., et al., Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 2018. 378(2): p. 113-125.
2. Planchard, D., et al., Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2018. 29(Suppl 4): p. iv192-iv237.
3. Mok, T.S., et al., Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med, 2017. 376(7): p. 629-640.
4. Sequist, L., et al., Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7. Annals of Oncology, 2017. 28: p. v482-v483.
5. Hochmair, M.J., et al., Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Future Oncol, 2018. 14(27): p. 2861-2874.
6. Sequist, L.V., et al., Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013. 31(27): p. 3327-34.
7. Soria, J.C., et al., Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol, 2015. 16(8): p. 990-8.
8. Lasalvia, P., et al., Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia. Expert Review of Pharmacoeconomics & Outcomes Research, 2021. 21(4): p. 821-827.
9. Westerink, L., et al., Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations. The European Journal of Health Economics, 2020. 21(6): p. 931-943.